Prognostic value of early left ventricular ejection fraction reserve during regadenoson stress solid-state SPECT-MPI

J Nucl Cardiol. 2022 Jun;29(3):1219-1230. doi: 10.1007/s12350-020-02420-w. Epub 2021 Jan 3.

Abstract

Background: We hypothesized early post-stress left ventricular ejection fraction reserve (EFR) on solid-state-SPECT is associated with major cardiac adverse events (MACE).

Methods: 151 patients (70 ± 12 years, male 50%) undergoing same-day rest/regadenoson stress 99mTc-sestamibi solid-state SPECT were followed for MACE. Rest imaging was performed in the upright and supine positions. Early stress imaging was started 2 minutes after the regadenoson injection in the supine position and followed by late stress acquisition in the upright position. Total perfusion deficit (TPD) and functional parameters were quantified automatically. EFR, ∆end-diastolic volume (EDV), and end-systolic volume (ESV) were calculated as the difference between stress and rest values in the same position. EFR < 0%, ∆EDV ≥ 5 ml, or ∆ESV ≥ 5 ml was defined as abnormal.

Results: During the follow-up (mean 3.2 years), 28 MACE occurred (19%). In Kaplan-Meier analysis, there was a significantly decreased event-free survival in patients with early EFR < 0% (P = 0.004). Similarly, there was a decreased event-free survival in patients with ∆ESV ≥ 5 ml at early stress (P = 0.003). However, EFR, ∆EDV, and ∆ESV at late stress were not associated with MACE-free survival. Cox proportional hazards model adjusting for clinical information and stress TPD demonstrated that EFR, ∆EDV, and ∆ESV at early stress were significantly associated with MACE (P < 0.05 for all).

Conclusions: Reduced early post-stress EFR on vasodilator stress solid-state SPECT is associated with MACE.

Keywords: Ejection fraction reserve; major cardiac adverse events; solid-state SPECT.

MeSH terms

  • Humans
  • Male
  • Prognosis
  • Purines
  • Pyrazoles
  • Stroke Volume
  • Tomography, Emission-Computed, Single-Photon / methods
  • Ventricular Dysfunction, Left* / diagnostic imaging
  • Ventricular Function, Left*

Substances

  • Purines
  • Pyrazoles
  • regadenoson